Private Equity's Infusion: SkyKnight's Bet on the Healthcare Shift to Home

SAN FRANCISCO, CA – July 24, 2026 – In a move that signals a deeper strategic alignment between private capital and the evolving healthcare landscape, infusion services provider Apex Infusion has announced a definitive partnership with private equity firm SkyKnight Capital. While the press release frames the deal as a growth-oriented collaboration, a closer analysis reveals it as a significant bet on one of the most powerful trends in modern medicine: the strategic migration of patient care away from costly hospital settings.

The transaction will see SkyKnight become the majority partner, injecting capital and strategic oversight to accelerate Apex's expansion. Crucially, Apex's clinician-led management team, including CEO Moussie Haile and Executive Chairman Rick Smith, will retain a significant ownership stake and continue to lead the company. FFL Partners, the incumbent private equity backer, will also roll over a portion of its investment, remaining a minority shareholder—a clear vote of confidence in Apex's future trajectory.

The New Economics of Infusion Care

To understand SkyKnight’s investment, one must first appreciate the seismic shifts occurring within the U.S. infusion therapy market, a sector currently valued at $118 billion and projected to surge to $193 billion by 2030. This explosive growth is not merely a function of a robust pharmaceutical pipeline delivering a new wave of infusible specialty drugs; it is fundamentally driven by a realignment of where, and how, care is delivered.

For decades, complex infusion therapies for conditions like cancer, autoimmune disorders, and rare diseases were the exclusive domain of hospitals. Today, a confluence of factors—payer pressure for cost containment, technological advancements in infusion technology, and a strong patient preference for convenience—is fueling an exodus to alternate sites of care. Apex Infusion operates at the heart of this transition with its “omnichannel” model, which combines a network of approximately 40 ambulatory infusion suites (AIS) with a fleet of home infusion nurses. This dual approach allows the company to capture patients wherever they are most comfortable and wherever care is most cost-effective. The market data validates this strategy: the U.S. ambulatory infusion center market is forecast to expand at over 10% annually, while the home infusion segment is projected to more than double to $46 billion by 2034.

A Calculated Bet on Regulatory Tailwinds

SkyKnight Capital, which manages roughly $6.5 billion, specializes in what it calls “acyclical growth sectors,” and the infusion market fits that description perfectly. The need for infusion therapy is driven by chronic disease, not economic cycles. The firm's investment in Apex is a calculated move to back a market leader in a sector bolstered by powerful regulatory and reimbursement tailwinds. As SkyKnight Managing Director Don Wu stated, “Our investment approach is guided by a firm belief that industry leaders are built by exceptional management teams delivering uncommon value.”

Federal policy is increasingly favoring the alternate site model that Apex has perfected. Payer-driven “site-neutral” payment policies are actively encouraging the migration of services from expensive hospital outpatient departments to more efficient freestanding centers. Furthermore, the Inflation Reduction Act recently enhanced Medicare Part B reimbursement for biosimilars, a staple of infusion therapy, creating more favorable economics for providers. Legislative efforts like the proposed “Preserving Patient Access to Home Infusion Act” aim to further improve Medicare reimbursement for home-based services, potentially unlocking a vast, underserved patient population. For a sophisticated investor like SkyKnight, these are not just policy details; they are foundational drivers of long-term value.

Scaling the Clinician-Led Model

While financial and regulatory dynamics make the sector attractive, the partnership's success will hinge on execution. Apex's leadership emphasizes that its clinical culture is its core differentiator. “What our team has built at Apex is something special – a best-in-class infusion platform designed to optimize the patient experience at every step,” said Moussie Haile, PharmD, CEO and co-founder of Apex. This sentiment underscores the delicate balance private equity must strike in healthcare: scaling a business without eroding the clinical quality that defines its brand.

The capital infusion from SkyKnight is earmarked for precisely this purpose: accelerating growth while maintaining a high standard of care. The stated goals include expanding into new geographic markets, forging strategic partnerships with health systems and payors, and investing in technology to enhance patient access and streamline operations. For patients with chronic conditions, this could mean more convenient locations, reduced wait times, and a more integrated care experience. “With SkyKnight and FFL, we are well positioned to accelerate our expansion and extend Apex’s model of care to more patients nationwide,” noted Rick Smith, Apex's Executive Chairman.

The Enduring Appeal for Investors

The continued participation of FFL Partners is a noteworthy element of the deal. Rather than executing a full exit, the firm is retaining a minority stake, a strategy that suggests a belief in significant remaining upside. “Apex has become a market leader within infusion treatment therapy, and the Company is well positioned to continue delivering high quality patient care,” commented Karen Winterhof, a Partner at FFL. This recapitalization allows FFL to de-risk its original investment while participating in the next phase of growth, now supercharged by SkyKnight's capital and expertise.

The partnership between Apex Infusion and SkyKnight Capital is more than a simple transaction; it is a microcosm of the broader transformation of the American healthcare system. It demonstrates how private capital, when aligned with strong clinical leadership and powerful market trends, can act as a potent catalyst for scaling new models of care that promise greater efficiency for payors and improved quality of life for patients.